MedTrace Logo

Study of MEDI 507 in the Treatment of Pediatric Patients

NCT00813618 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2008-12-23

No results posted yet for this study

Summary

To assess the safety of escalating dose levels of MEDI-507 in pediatric stem cell and bone marrow allograft recipients who have at least Grade II GvHD.

Conditions

Interventions

DRUG

MEDI-507

0.012 mg/kg given intravenously on Study Days 0, 3, 6 and 9

DRUG

MEDI-507

0.04 mg/kg given intravenously on Study Days 0, 3, 6 and 9

DRUG

MEDI-507

0.12 mg/kg given intravenously on Study Days 0, 3, 6 and 9

Sponsors & Collaborators

  • MedImmune LLC

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-09-30
Primary Completion
2004-06-30
Completion
2004-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00813618 on ClinicalTrials.gov